Hyperhomocysteinemia and thrombosis

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue 3, 1999, Pages 291-309

  Guba, Susan C ^a,b   Fonseca, Vivian ^a   Fink, Louis M ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Atherosclerosis; Homocysteine; Methionine; Thrombosis; Vitamins

Indexed keywords

AGE; ATHEROSCLEROSIS; CONFERENCE PAPER; DISEASE ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; HYPERHOMOCYSTEINEMIA; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; THROMBOSIS; VEIN OCCLUSION; VITAMIN BLOOD LEVEL;

EID: 0032783269     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-994932     Document Type: Conference Paper

References (181)

1. McCully K. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-128
2. McCully K. The Homocysteine Revolution. New Canaan. Keats Publishing, Inc, 1997
3. Wilcken D, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 1976;57:1079-1082
4. Aronow W, Ahn C. Association between plasma homocysteine and coronary artery disease in older persons. Am J Cardiol 1997;80:1216-1218
5. Boers G, Smals A, Trijbels F, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985;313:709-715
6. Boushey C, Beresford S, Omenn G, Motulsky A. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049-1057
7. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 1991;324:1149-1155
8. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997;90:1-11
9. 6, pyridoxal phosphate, and folate. Am J Cardiol 1995;75:1107-1111
10. den Heijer M, Koster T, Blom H, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-762
11. De Stefano V, Finazzi G, Mannucci P. Inherited thrombophilia: Pathogenesis, clinical syndromes, and management. Blood 1996;87:3531-3544
12. Falcon C, Cattaneo M, Panzeri D, Martinelli I, Mannucci P. High prevalence of hyperhomocysteinemia with juvenile venous thrombosis. Arterioscler Thromb 1994; 14:1080-1083
13. Fermo I, Vigano' D'Angelo V, Paroni R, et al. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995;123:747-753
14. Freyburger G, Labrouche S, Sassoust G, et al. Mild hyperhomocysteinemia and hemostatic factors in patients with arterial vascular diseases. Thromb Haemost 1997;77:466-471
15. Frosst P, Blom H, Milos R, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995;10:111-113
16. Glueck C, Shaw P, Lang J, et al. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 1995;75:132-136
17. Graham I, Daly L, Refsum H, et al. Plasma homocysteine as a risk factor for vascular disease. JAMA 1997;277:1775-1781
18. Guba S, Fink L, Fonseca V. Hyperhomocysteinemia: An emerging and important risk factor for thromboembolic and cardiovascular disease. Am J Clin Pathol 1996;105:709-722
19. Guba S, Fink L, Fonseca V. Hyperhomocysteinemia and premature vascular occlusive disease. Am J Med Sci 1998;315: 279-285
20. Hopkins P, Wu L, Wu J, et al. Higher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1995;15:1314-1320
21. Hoogeveen E, Kostense P, Beks P, et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus. A population based study. Arterioscler Thromb Vasc Biol 1998;18:133-138
22. Kang S, Passen E, Ruggie N, Wong P, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1993;88:1463-1469
23. Kluijtmans L, van den Heuvel L, Boers G, et al. Molecular genetic analysis in mild hyperhomocysteinemia: A common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996;58:35-41
24. Konechy N, Malinow M, Tunick P, et al. Correlation between plasma homocyst(e)ine and aortic atherosclerosis. Am Heart J 1997;133:534-540
25. Kottke-Marchant K, Green R, Jacobsen D, et al. High plasma homocysteine: A risk factor for arterial and venous thrombosis in patients with normal coagulation profiles. Clin Appl Thromb/Hemost 1997;3:239-244
26. Lindgren A, Brattstrom L, Norrving B, et al. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995;26:795-800
27. Malinow M, Sexton G, Averbuch M, et al. Homosyt(e)inemia in daily practice: Levels in coronary artery disease. Coronary Artery Disease 1990;1:215-220
28. Malinow M, Nieto F, Szklo M, Chambless L, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. Circulation 1993;87:1107-1113
29. Malinow M, Kang S, Taylor L, et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989;79:1180-1188
30. Malinow M. Plasma homocyst(e)ine and arterial occlusive diseases: A mini-review. Clin Chem 1995;41:173-176
31. Malinow M. Plasma homocyst(e)ine: A risk factor for arterial oclusive diseases. J Nutr 1996;126:1238S-1243S
32. Mandel H, Brenner B, Berant M, et al. Coexistence of hereditary homocystinuria and factor V Leiden - Effect on thrombosis. N Engl J Med 1996;334:763-768
33. Motulsky A. Nutritional ecogenetics: Homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am J Hum Genet 1996;58:17-20
34. Nehler M, Taylor LJ, Porter J. Homocysteinemia as a risk factor for atherosclerosis: A review. Cardiovasc Surg 1997;5:559-567
35. Nygard O, Vollset S, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile: The Hordaland homocysteine study. JAMA 1995;274:1526-1533
36. Nygard O, Nordrehaug J, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;1337:230-236
37. Refsum H, Ueland P, Nygard O, Vollset S. Homocysteine and cardiovascular disease. Annu Rev Med 1998;49:31-62
38. Ridker P, Hennekens C, Selhub J, et al. Interrelation of hyperhomocyst(e)inemia. Factor V Leiden, and risk of future venous thromboembolism. Circulation 1997;95:1777-1782
39. Stampfer M, Malinow M, Willett W, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-881
40. Selhub J, Jacques P, Bostom A, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995;332:286-291
41. Superko H. Elevated high-density lipoprotein cholesterol, not protective in the presence of homocysteinemia. Am J Cardiol 1997;79:705-706
42. 12 and folate. Am J Epidemiol 1996;143:845-859
43. Verhoef P, Kok F, Kruyssen D, et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arteriosclerosis Thromb Vasc Biol 1997;17:989-995
44. Verhoef P, Hennekens C, Allen R, et al. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. Am J Cardiol 1997;79:799-801
45. Verhoef P, Hennekens C, Malinow M, et al. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994;25:1924-1930
46. Voutilainen S, Alfthan G, Nyyssonen K, Salonen R, Salonen J. Association between elevated plasma total homocysteine and increased common carotid artery wall thickness. Ann Med 1998;30:300-306
47. Wald N, Watt H, Law M, et al. Homocysteine and ischemic heart disease. Arch Intern Med 1998;158:862-867
48. Wu L, Wu J, Hunt S, et al. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin Chem 1994;40:552-561
49. Mudd S, Levy H. Plasma homocyst(e)ine or homocysteine? N Engl J Med 1995;333:325
50. Ueland P, Refsum H, Stabler S, et al. Total homocysteine in plasma or serum: Methods in clinical applications. Clin Chem 1993;39:1764-1779
51. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987;422:43-52
52. Ubbink J, Vermaak W, Bissbort S. Rapid high performance liquid chromatographic assay for total homocysteine levels in human serum. Eur J Clin Chem Clin Biol Chem 1991;29:549-554
53. Fiskerstrand T, Refsum H, Kvalheim G, Eulan P. Homocysteine and other thiols in plasma and urine: Automated determination in sample stability. Clin Chem 1993;39:263-271
54. Evrovski J, Kalaghan M, Cole D. Determination of homocysteine by HPLC with pulsed integrated amperometry. Clin Chem 1995;41:757-758
55. Anderson A, Isaksson A, Brattstrom L, Hultberg B. Homocysteine and other thiols determined in plasma by HPLC and thiol-specific postcolumn derivatization. Clin Chem 1993;39:1590-1597
56. Shipchandler M, Moore E. Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott Imx Analyser. Clin Chem 1995;41:991-994
57. van der Griend R, Haas F, Duran M, et al. Methionine loading test is necessary for detection of hyperhomocysteinemia. J Lab Clin Med 1998;132:67-72
58. Lombardi R, Cattaneo M, Agati B, et al. Comparison between the 2-hour and the 4-hour methionine loading test for the identification of subjects with methionine intolerance. Thromb Res 1998;91(Suppl 1):S16-S17
59. Munshi M, Stone A, Fink L, Fonseca V. Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease. Metabolism 1996;45:133-135
60. Lentz S, Sobey C, Piegors D, et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 1996;98:24-29
61. Durand P, Prost M, Blache D. Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n-3 polyunsaturated fatty acids. Atherosclerosis 1996;121:231-243
62. Durand P, Lussier-Cacan S, Blache D. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB Lett 1997;11:1157-1168
63. Hanratty C, McAuley D, McGurk C, Young I, Johnston G. Homocysteine and endothelial vascular function (letter). Lancet 1998;351:1288-1289
64. Southern F, Cruz N, Fink L, et al. Hyperhomocysteinemia increases intimal hyperplasia in a rat carotid endarterectomy model. J Vasc Surg 1998;28:909-918
65. Mudd S, Levy H, Skovby F. Disorders of transsulfuration. In: Scriver C, Beaudet A, Sly W, et al, eds: The Metabolic Basis of Inherited Disease (Ed 7th). New York: McGraw-Hill, 1995;1279-1327
66. Welch G, Upchurch G, Loscalzo J. Homocysteine, oxidative stress, and vascular disease. Hosp Pract 1997;32:81-92
67. Finkelstein J, Lyle W, Martin J, Pick A. Activation of cystathionine synthase by adenosylmethionine and adenosylethionine. Biochem Biophys Res Commun 1975;66:81-87
68. Jencks D, Matthews R. Allosteric inhibition of methylenetetrahydrofolate reductase by adenosylmethionine. J Biol Chem 1987;262:2485-2493
69. Visy J, Le Coz P, Chadefaux B, et al. Homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency revealed by stroke in adult siblings. Neurology 1991;41:1313-1315
70. Jacobsen D, Savon S, Stewart R, et al. Limited capacity for homocysteine catabolism in vascular cells and tissues: A patho-physiologic mechanism for arterial damage in hyperhomocysteinemia? (Abstract). Circulation 1995;92:I-228
71. Joosten E, Pelemans W, Devos P, et al. Cobalamin absorption and serum homocysteine and methylmalonic acid in elderly subjects with low serum cohalamin. Eur J Hematol 1993;51:25-30
72. Selhub J, Jacques P, Wilson P, Rush D, Rosenberg I. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-2698
73. Wouters M, Moorrees M, van der Mooren M, et al. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995;25:801-805
74. van der Mooren M, Wouters M, Blom H, et al. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest 1994;24:733-736
75. Anker G, Lonning P, Ueland P, Refsum H, Lien E. Plasma levels of the atherogenic amino acid homocysteine in postmenopausal women with breast cancer treated with tamoxifen. Cancer 1995;60:365-368
76. Cattaneo M, Baglietto L, Zighetti M, et al. Tamoxifen reduces plasma homocysteine levels in healthy women. Br J Cancer 1998;77:2264-2266
77. Stein J, McBride P. Hyperhomocysteinemia and atherosclerotic vascular disease. Arch Intern Med 1998;158:1301-1306
78. Nedrebo B, Ericsson U-B, Nygard O, et al. Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism 1998;47:89-93
79. Bostom A, Brosnan J, Hall B, Nadeau M, Selhub J. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 1995;116:59-62
80. Bostom A, Shemin D, Lapane K, et al. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996;49:147-152
81. Fonseca V, Guba S, Fink L. Hyperhomocysteinemia and the endocrine system: Implications for atherosclerosis and thrombosis. Endocrine Rev in press, 1999
82. Hoffman M, Kohl B, Zumbach M, et al. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 1997;20:1880-1886
83. Hoffman M, Kohl B, Zumbach M, et al. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 1998;21:841-848
84. Bostom A, Gohh R, Tsai M, et al. Excess prevalence of fasting and postmethionine-loading hyperhomocysteinemia in stable renal transplant patients. Arteriosclerosis Thromb Vasc Biol 1997;17:1894-1900
85. Bostom A, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997;52:10-20
86. Rozen R. Genetic predisposition to hyperhomocysteinemia: Deficiency of methylenetetrahydrofolate reductase (MTHFR). Thromb Haemost 1997;78:523-526
87. Stampfer M, Malinow M. Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med 1995;332:328-329
88. van der Put N, van der Molen E, Kluijtmans L, et al. Sequence analysis of the coding region of human methionine synthase: Relevance to hyperhomocysteinaemia in neural tube defects and vascular disease. Q J Med 1997;90:511-517
89. Fenton W, Rosenberg L. Inherited disorders of cobalamin transport and metabolism. In: Scriver C, Beaudet A, Sly W, et al, eds: The Metabolic Basis of Inherited Disease (Ed. 7th). New York: McGraw-Hill, Inc, 1995:3129-3149
90. Kraus J, Le K, Swaroop M, et al. Human cystathionine β-synthase cDNA: Sequence, alternate splicing and expression in cultured cells. Hum Mol Genet 1993;2:1633-1638
91. Kluijtmans L, Blom H, Boers G, et al. Two novel missense mutations in the cystathionine β-synthase gene in homocystinuric patients. Hum Genet 1995;96:249-250
92. Tsai M, Hansom N, Schwichtenberg K, Garg U. Amplification refractory mutation system to identify mutations in cystathionine β-synthase deficiency. Clin Chem 1995;41:1775-1777
93. Giusti B, Comeglio P, Attanasio M, et al. Different distribution of the double mutant "T833C/68 bp insertion" in cystathionine β-synthase gene in northern and southern Italian populations. Thromb Haemost 1997;78:1293 (Abst)
94. Kraus J, Williamson C, Firgaira F, et al. Cloning and screening with nanogram amounts of immunopurified messenger RNAs, cDNA cloning and chromosomal mapping of cystathionine β-synthase and the β-subunit of propionyl CoA carboxylase. Proc Natl Acad Sci USA 1986;83:2047-2051
95. Munke M, Kraus J, Ohura T, Francke U. The gene for cystathionine β-synthase (CBS) maps to the subtelomeric region of human chromosome 21q to proximal mouse chromosome 17. Am J Hum Genet 1988;42:550-559
96. McGill J, Mettler G, Rosenblatt D, Scriver C. Detection of heterozygotes for recessive alleles. Homocyst(e)inemia: Paradigm of pitfalls in phenotypes. Am J Med Genet 1990;36:45-52
97. Boddie A, Steen M, Sullivan K, et al. Cystathionine β-synthase deficiency: Detection of heterozygotes by the ratios of homocysteine to cysteine and folate. Metabolism 1998;47:207-211
98. Tsai M, Garg U, Key N, et al. Molecular and biochemical approaches in the identification of heterozygotes for homocystinuria. Atherosclerosis 1996;122:69-77
99. Kluijtmans L, Boers G, Stevens E, et al. Defective cystathionine β-synthase regulation by S-adenosylmethionine in a partially pyridoxine responsive homocystinuria patient. J Clin Invest 1996;98:285-289
100. Tsai M, Hanson N, Bignell M, Schwichtenberg K. Simultaneous detection and screening of T833C and G919A mutations of the cystathionine β-synthase gene by single-strand conformational polymorphism. Clin Biochem 1996;29:473-477
101. Sebastio G, Sperandeo M, Panico M, et al. The molecular basis of homocystinuria due to cystathionine β-synthase deficiency in Italian families, and report of four novel mutations. Am J Hum Genet 1995;56:1324-1333
102. Sperandeo M, De Franchis R, Andria G, Sebastio G. A 68-bp insertion found in a homocystinuric patient is a common variant and is skipped by alternative splicing of the cystathionine β-synthase mRNA (letter). Am J Hum Genet 1996; 59:1391-1393
103. Tsai M, Bignell M, Schwichtenberg K, Hanson N. High prevalence of a mutation in the cystathionine β-synthase gene. Am J Hum Genet 1996;59:1262-1267
104. Comeglio P, Pepe G, Camacho-Vanegas O, et al. Prevalence of the T833/68 bp INS mutation in cystathionine β-synthase gene in different ethnic groups. Thromb Res 1998;91(Suppl 1):S87 (Abst)
105. Goyette P, Sumner J, Milos R, et al. Human methylenetetrahydrofolate reductase isolation of cDNA, mappng and mutation identification. Nature Genet 1994;7:195-200
106. Goyette P, Sumner J, Milos R, et al. Human methylenetetrahydrofolate reductase isolation of cDNA, mapping and mutation identification, Errata. Nature Genet 1994;7:551
107. Kang S, Wong P, Susmano A, et al. Thermolabile methylenetetrahydrofolate reductase: An inherited risk factor for coronary artery disease. Am J Hum Genet 1991;48:536-545
108. Brown A, Fonseca V, Fink L, Guba S, Unpublished observation. 1998
109. McAndrew P, Brandt J, Pearl, Prior T. The incidence of the gene for thermolabile methylene tetrahydrofolate reductase in African Americans. Thromb Res 1996;83:195-198
110. Jacques P, Bostom A, Williams R, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7-9
111. Ma J, Stampfer M, Hennekens C, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996;94:2410-2416
112. Pinto G, Galleni A, De Cassan P, Barone E, Perroni L. The mutant C677-T of the MTHFR gene is not a risk factor for thrombosis. Thromb Res 1998;91:S30(Abst)
113. Chen L, Liu M-L, Hwang H-Y, et al. Human methionine synthase. J Biol Chem 1997;272:3628-3634
114. 12-responsive neonatal megaloblastic anemia and homocystinuria with associated reduced methionine synthase activity. Blood 1987;69:1128-1133
115. Harding C, Arnold G, Barness L, Wolff J, Rosenblatt D. Functional methionine synthase deficiency due to cblG disorder: A report of two patients and a review. Am J Med Genet 1997;71:384-390
116. Fowler B, Schutgens R, Rosenblatt D, Smit G, Lindemans J. Folate-responsive homocystinuria and megaloblastic anaemia in a female patient with functional methionine synthase deficiency (cblE disease). J Inherit Metab Dis 1997;20:731-741
117. Rosenblatt D, Aspler A, Shevell M, et al. Clinical heterogeneity and prognosis in combined methylmalonic aciduria and homocystinuria (cblC). J Inherit Metab Dis 1997;20:528-538
118. Gulati S, Baker P, Li Y, et al. Defects in human methionine synthase in cblG patients. Hum Mol Genet 1996;5:1859-1865
119. Nygard O, Refsum H, Ueland P, Vollset S. Major lifestyle determinants of plasma total homocysteine distribution: The Hordaland homocysteine study. Am J Clin Nutr 1998;67:263-270
120. Landgren F, Israelsson B, Lindgren A, et al. Plasma homocysteine in acute myocardial infarction: Homocysteine-lowering effect of folic acid. J Intern Med 1995;237:196-199
121. Kuller L, Evans R. Homocysteine, vitamins, and cardiovascular disease. Circulation 1998;98:196-199
122. Evans R, Shaten J, Hempel J, Cutler J, Kuller L, for the MRFIT Research Group. Homocyst(e)ine and risk of cardiovascular disease in the multiple risk factor intervention trial. Arteriosclerosis Thromb Vasc Biol 1997;17:1947-1953
123. Folsom A, Nieto F, McGovern P, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. Circulation 1998;98:204-210
124. Molgaard J, Malinow M, Lassvik C, et al. Hyperhomocyst(e)inemia: An independent risk factor for claudication. J Intern Med 1992;231:273-279
125. Robinson K, Mayer E, Miller D, et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995;92:2825-2830
126. 6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998;279:359-364
127. den Heijer M, Brouwer I, Bos G, et al. Vitamin supplementation reduces blood homocysteine levels. A controlled trial in patients with venous thrombosis and healthy volunteers. Arteriosclerosis Thromb Vasc Biol 1998;18;356-361
128. Eichinger S, Stumpflen A, Hirschl M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998;80:566-569
129. Legnani C, Palareti G, Grauso F, et al. Hyperhomocyst(e)inemia and a common methylenetetrahydrofolate reductase mutation (Ala223Val MTHFR) in patients with inherited thrombophilic coagulation defects. Arteriosclerosis Thromb Vasc Biol 1997;17:2924-2929
130. Kluijtmans L, Boers G, Verbruggen B, et al. Homozygous cystathionine β-synthase deficiency, combined with Factor V Leiden or thermolabile methylenetetrahydrofolate reductase in the risk of venous thrombosis. Blood 1998;91:2015-2018
131. Malinow M, Nieto F, Kruger W, et al. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arteriosclerosis Thromb Vasc Biol 1997;17:1157-1162
132. Christensen B, Frosst P, Lussier-Cacan S, et al. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arteriosclerosis Thromb Vasc Biol 1997;17:569-573
133. Ali N, Powell J, Swaminathan R, Markus H. The relationship between MTHFR genotype, serum homocysteine and folate levels. Biochem Soc Trans 1997;25:386S
134. Lalouschek W, Aull S, Kominger L, et al. 677C to T mutation in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene and plasma homocyst(e)ine levels in patients with TIA or minor stroke. Neurol Sci 1998;155:156-162
135. de Franchis R, Buoninconti A, Fermo I, et al. Increased thrombotic risk for patients with associated 844ins68 mutation of the CBS gene and the 677C-T mutation of the MTHFR gene. Thromb Res 1998;91 (Suppl 1):S3 (Abst)
136. Jacobsen D. Homocysteine and vitamins in cardiovascular disease. Clin Chem 1998;44:1833-1843
137. Mayer E, Jacobsen D, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27:517-527
138. Selhub J, D'Angelo A. Relationship between homocysteine and thrombotic disease. Am J Med Sci 1998;316:129-141
139. Welch G, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-1050
140. Lentz S. Minireview Homocysteine and vascular dysfunction. Life Sciences 1997;61:1205-1215
141. Stamler J, Osborne J, Jaraki O, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91:308-318
142. Harpel P, Zhang X, Borth W. Homocysteine and hemostasis: Pathogenetic mechanisms predisposing to thrombosis. J Nutr 1996;126:1285S-1289S
143. Lieberman E, Gomperts E, Shaw K, Landing B, Donnell G. Homocystinuria: Clinical and pathologic review, with emphasis on thrombotic features, including pulmonary artery thrombosis. In: Landing B, Haust M, Bernstein J, et al, eds: Genetic Metabolic Diseases. Perspect Pediatr Pathol. Basel: Karger, 1993:125-147
144. Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures. Possible mechanism for pathological consequences of elevated homocysteine levels. J Biol Chem 1997;272:1935-1942
145. Upchurch GJ, Welch G, Loscalzo J. Homocysteine, EDRF and endothelial function. J Nutr 1996;126:1290S-1294S
146. Upchurch GJ, Welch G, Fabian A, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997;272:17012-17017
147. Starkebaum G, Harlan J. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986;77:1370-1376
148. McCully K, Ragsdale B. Production of arteriosclerosis by homocysteinemia. Am J Pathol 1970;61:1-8
149. McCully K, Wilson R. Homocysteine theory of arteriosclerosis. Atherosclerosis 1975;22:215-227
150. Harker L, Harian J, Ross R. Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. Circ Res 1983;53:731-739
151. Stamler J, Loscalzo J. Endothelium-derived relaxing factor modulates the atherothrombogenic effects of homocysteine. J Cardiol Pharmacol 1992;20:S202-S204
152. Upchurch GJ, Welch G, Ramdev M, et al. The effects of homocysteine in endothelial nitric oxide production. FASEB Lett 1995;9:A876(Abst)
153. Blom H, Kleinveld H, Boers G, et al. Lipid peroxidation and susceptibility of low-density lipoprotein to in vitro oxidation in hyperhomocysteinaemia. Eur J Clin Invest 1995;25:149-154
154. de Groot P, Willems C, Boers G, et al. Endothelial cell dysfunction in homocystinuria. Eur J Clin Invest 1983;13:405-410
155. Celermajer D, Sorensen K, Ryalls M, et al. Impaired endotheial function occurs in the systemic arteries of children with homozygous homocytinuria but not in their heterozygous parents. J Am Coll Cardiol 1993;22:854-858
156. Tawakol A, Omland P, Gerhard M, Wu J, Creager M. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997;95:1119-1121
157. Woo K, Chook P, Lolin Y, et al. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997;96:2542-2544
158. Tsai J, Perrella M, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA 1994;91:6369-6373
159. Tsai J-C, Wang H, Perrella M, et al. Induction of cyclin A gene expressin by homocysteine in vascular smooth muscle cells. J Clin Invest 1996;97:146-153
160. Welch G, Upchurch G, Farivar R, et al. Homocysteine-induced nitric oxide production in vascular smooth muscle cells by NF-kB dependent transcriptional activation of Nos 2. Proc Am Assoc Phys 1998;110:22-31
161. Majors A, Ehrhart L, Pezacka E. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arteriosclerosis Thromb Vasc Biol 1997;17:2074-2081
162. ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 1997;272:25380-25385
163. McCully K. Chemical pathology of homocysteine I. Atherogenesis. Ann Clin Lab Sci 1993;23:477-493
164. Poddar R, Sivasubramanian N, Robinson K, Jacobsen D. Homocysteine modulates the expression of a specific cytokine (monocyte chemoattractant protein-I) in human aortic endothelial cells. Circulation 1997;96:I-286, (Abst)
165. Harker L, Ross R, Slichter S, Scott C. Homocystine-induced arteriosclerosis: The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976:58:731-741
166. Di Minno G, Davi G, Margaglione M, et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest 1993;92:1400-1406
167. Ratnoff O. Activation of Hagemann factor by L-homocystine. Science 1968;162:1007-1009
168. Rodgers G, Conn M. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990;75:895-901
169. Fryer R, Wilson B, Gubler D, Fitzgerald L, Rodgers G. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arteriosclerosis Thromb Vasc Biol 1993;13:405-410
170. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993;92:1381-1386
171. Hajjar K, Mauri L, Jacovina A, et al. Tissue plasminogen activator binding to the annexin II tail domain. J Biol Chem 1998; 273:9987-9993
172. Lentz S, Sadler J. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991;88:1906-1914
173. Coppola A, Albisinni R, Madonna P, et al. Platelet and monocyte variables in homocystinuria due to cystathionine-beta-synthase deficiency. Haematologica 1997;92:189-90
174. Malinow M, Duell P, Hess D, et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998;338:1009-1115
175. Stampfer M. Homocysteine levels and cardiovascular disease. Am Family Phys 1997;56:1568, 1571-1572
176. Brattstrom L. Vitamins as homocysteine-lowering agents. J Nutr 1996;126:1276S-1280S
177. Van den Berg M, Boers G, Franken D, et al. Hyperhomocysteinemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995;25:176-181
178. Schienle H, Seitz R, Rohner I, et al. Coagulation factors and markers of activation of coagulation in homocystinuria (HOCY): A study in two siblings. Blood Coag Fibrinolysis 1994;5:873-878
179. Kyrle PA, Stumpflen A, Hirschl M, et al. Levels of prothrombin fragment F1+2 in patients with hyperhomocysteinemia and a history of venous thromboembolism. Thromb Haemost 1997;78:1327-1231
180. Jacob R, Gretz D, Taylor P, et al. Moderate folate depletion increases plasma homocysteine and decreases lymphocyte DNA methylation in postmenopausal women. J Nutr 1998;128:1204-1212
181. Woodside J, Yamell J, McMaster D, et al. Effect of B-group vitamins and antioxidant vitamins on hyperhomocysteinemia: A double-blind, randomized, factorial-design, controlled trial. Am J Clin Nutr 1998;67:858-866